Compass Pathways Plc (CMPS)
7.90
-0.75
(-8.67%)
USD |
NASDAQ |
Nov 20, 10:35
Compass Pathways Cash from Operations (Quarterly) : -50.74M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -50.74M |
| June 30, 2026 | -40.37M |
| March 31, 2026 | -47.86M |
| December 31, 2025 | -37.73M |
| September 30, 2025 | -34.81M |
| June 30, 2025 | -39.24M |
| March 31, 2025 | -45.83M |
| December 31, 2024 | -41.46M |
| September 30, 2024 | -22.52M |
| June 30, 2024 | -34.45M |
| March 31, 2024 | -20.82M |
| December 31, 2023 | -27.85M |
| September 30, 2023 | -17.99M |
| June 30, 2023 | -24.42M |
| Date | Value |
|---|---|
| March 31, 2023 | -27.49M |
| December 31, 2022 | -45.33M |
| September 30, 2022 | -17.10M |
| June 30, 2022 | -17.89M |
| March 31, 2022 | -22.99M |
| December 31, 2021 | -22.26M |
| September 30, 2021 | -13.98M |
| June 30, 2021 | -17.68M |
| March 31, 2021 | -13.83M |
| December 31, 2020 | -16.75M |
| September 30, 2020 | -13.91M |
| June 30, 2020 | -6.251M |
| March 31, 2020 | -4.463M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Silence Therapeutics Plc | -12.79M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -2.037M |
| Mereo BioPharma Group Plc | -4.048M |
| HemoGenyx Pharmaceuticals Plc | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 63.01M |
| Free Cash Flow | -176.69M |
| Free Cash Flow Per Share (Quarterly) | -0.3121 |
| Free Cash Flow to Equity (Quarterly) | -50.50M |
| Free Cash Flow to Firm (Quarterly) | -49.60M |
| Free Cash Flow Yield | -15.79% |